Page last updated: 2024-11-11

antibiotic 1233a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

antibiotic 1233A: beta-lactone antibiotic from Cephalosporium; hydroxymethylglutaryl-CoA synthase & 3C protease, viral inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6440895
CHEMBL ID470269
CHEBI ID191049
SCHEMBL ID613745
MeSH IDM0153368

Synonyms (28)

Synonym
2,4-undecadienoic acid, 11-(3-(hydroxymethyl)-4-oxo-2-oxetanyl)-3,5,7-trimethyl-, (2r-(2-alpha(2e,4e,7r*),3-beta))-
antibiotic f 244
f-244
antibiotic 1233a
l 659699
f 244
1233a
CHEMBL470269
hymeglusin
CHEBI:191049
29066-42-0
(2e,4e,7r)-11-[(2r,3r)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoic acid
l-659,699
gtpl5886
SCHEMBL613745
HB3701
(r,r)-hymeglusin
J-017379
AKOS032946337
Q27078398
2,4-undecadienoic acid, 11-[(2r,3r)-3-(hydroxymethyl)-4-oxo-2-oxetanyl]-3,5,7-trimethyl-, (2e,4e,7r)-
11-[3r-(hydroxymethyl)-4-oxo-2r-oxetanyl]-3,5,7r-trimethyl-2e,4e-undecadienoic acid
l 659,699
l659,699
HY-117430
DTXSID901318499
CS-0065979
(r,2e,4e)-11-((2r,3r)-3-(hydroxymethyl)-4-oxooxetan-2-yl)-3,5,7-trimethylundeca-2,4-dienoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Mevalonate arm of cholesterol biosynthesis pathway with inhibitors214

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1778125Antimicrobial activity against Bacillus anthracis assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay2021Journal of natural products, 04-23, Volume: 84, Issue:4
Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.
AID1778129Antimicrobial activity against Pseudomonas aeruginosa assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay2021Journal of natural products, 04-23, Volume: 84, Issue:4
Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.
AID1778127Antimicrobial activity against Staphylococcus aureus assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay2021Journal of natural products, 04-23, Volume: 84, Issue:4
Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.
AID1778126Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay2021Journal of natural products, 04-23, Volume: 84, Issue:4
Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.
AID1631437Antiviral activity against Dengue virus 2 NGC infected in human K562 cells assessed as inhibition in live viral replication after 48 hrs by plaque assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1778128Antimicrobial activity against Escherichia coli assessed as microbial growth inhibition by CLSI-protocol based broth microdilution assay2021Journal of natural products, 04-23, Volume: 84, Issue:4
Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations.
AID1346846Rat hydroxymethylglutaryl-CoA synthase 1 (Lanosterol biosynthesis pathway)1987Proceedings of the National Academy of Sciences of the United States of America, Nov, Volume: 84, Issue:21
Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699.
AID1346846Rat hydroxymethylglutaryl-CoA synthase 1 (Lanosterol biosynthesis pathway)1993The Biochemical journal, Feb-01, Volume: 289 ( Pt 3)Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by beta-lactone inhibitors and binding of these inhibitors to the enzyme.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (13.33)18.7374
1990's13 (43.33)18.2507
2000's7 (23.33)29.6817
2010's2 (6.67)24.3611
2020's4 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]